E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Estrogen receptor positive metastatic or locally advanced inoperable breast cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced breast cancer that is sensitive to endocrine treatment. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006192 |
E.1.2 | Term | Breast cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study superiority of the combination of endocrine based treatment and atorvastatin when compared to endocrine based treatment
alone, in terms of clinical benefit rate, Progression Free Survival (PFS), Objective Response Rate (ORR; the proportion of patients with a best
overall response- complete response or partial response), Time-To-Progression (TTP), Duration of Clinical Benefit (DCB), Overall Survival (OS).
|
|
E.2.2 | Secondary objectives of the trial |
To establish safety and tolerability of the combination of endocrine based treatment with atorvastatin.
To elucidate mechanisms of resistance to endocrine based treatment alone or in combination with statins in ER+ metastatic breast cancer.
Translational:
1. To study treatment effects in terms of tumor marker expression in primary tumor, the untreated metastatic tumor, and upon progression
2. To analyse circulating markers measured at inclusion, every third month, and upon progression (e.g. biomarkers of
immunology, lipid-metabolism, and endocrine response as well as circulating tumor DNA)
3. To establish a comparison in the genomic profile of the circulating tumor DNA (ctDNA) and the biopsies of the metastatic lesions. Evaluate
the findings of the genomic changes in ctDNA before treatment and upon progression to endocrine based treatment
with those in the FFPE biopsies obtained at the same time points.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients diagnosed with ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic
endocrine based treatment. If IHC analysis is not available from the metastatic tissue, the ER and HER2 status is determined from archived
primary tumor.
2. Age > 18 years.
3. Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2.
4. Metastatic disease must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination,
computerized tomography (CT), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET). Bone
metastases alone are allowed.
5. Pre-menopausal patients must consent to undergo either surgical or chemical castration during the duration of the treatment and utilize an
effective contraception barrier method.
6. Patient not willing to undergo study specific biopsy from the metastatic site should preferably have enough metastatic tumor sample
material archived to perform DNA extraction from formalin fixed paraffin embedded (FFPE) material.
7. Patient must be capable and willing to grant signed informed consent prior to any procedure related with this study as well as to allow
access to FFPE biopsies for DNA extraction and for serial CTCs ctDNA analysis. Biopsy of the metastatic site upon progression is not
mandatory but desirable.
8. Signed informed consent according to ICH/GCP, and national/local regulations.
|
|
E.4 | Principal exclusion criteria |
1. Previous treatment for metastatic breast cancer (previous systemic treatment for early breast cancer allowed).
2. Brain as the only site of metastatic breast cancer.
3. Ongoing treatment with statins (e.g. simvastatin, atorvastatin, fluvastatin, lovastatin, pravastatin, or rosuvastatin), anion-exchangers (e.g.
colestyramin or colesevelam), fibrates (e.g. gemfibrozil), nicotin-acids (or acipimox) or inhibitors of intestinal cholesterol uptake (e.g.
ezitimibe) for the first part of the trial.
4. Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal
dysfunction (creatine kinase level) more than three times the upper limit of the normal range.
5. The patient is unable to pause treatment with anticoagulants/antiagregants prior to biopsy during the recommended times.
6. History of haemorrhagic stroke.
7. Pregnancy or breast-feeding.
8. Untreated psychiatric disorders that will impair the patient’s ability to comply with study treatment or protocol.
9. History of allergic reactions attributed to compounds of similar chemical or biological composition to either of the study drugs.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical benefit rate, defined as the proportion of all randomly assigned patients who have the best overall response rate at cut-off time for data analysis following first-line endocrine based therapy alone contrasted to endocrine based therapy plus atorvastatin. Data cut-off time has been pre-specified as 9 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Clinical benefit rate, which is defined as the proportion of all randomly assigned patients who have a best overall response of a complete response (CR), a partial response (PR), or stable disease (SD) for at least 24 weeks following first-line letrozole treatment vs. letrozole and atorvastatin. |
|
E.5.2 | Secondary end point(s) |
1) Progression free survival comparing endocrine based treatment alone or endocrine based treatment in combination with atorvastatin in
patients with metastatic breast cancer.
2) Objective Response Rate (ORR; the proportion of patients with a best overall response- complete response or partial response).
3) Time-To-Progression (TTP).
4) Duration of Clinical Benefit (DCB).
5) Overall survival.
6) Safety and tolerability
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Progression free survival (PFS) is defined as the time elapsing between the time of random assignment to treatment and the date of the earliest evidence of objective disease progression or death of any cause before documented disease-progression.
2. Time-To-Progression (TTP) defined as time elapsed between date of diagnosis of metastatic disease and date of confirmation of disease progression in the first part of the protocol.
3. Duration of Clinical Benefit (DCB) includes complete response, partial response and disease stabilization.
4. Overall survival defined as the time elapsed from the date of first confirmation of metastatic disease and the date of death from any cause. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Translational:
To study treatment effects in terms of molecular profile (genomic and transcriptomic) in primary tumor, the untreated metastatic tumor,
and upon progression.
|
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end once the last recruited patient has been in treatment for 9 months. This is so because of the primary end-point of clinical benefit rate. 9 months is the pre-specified time to be able to evaluate either stable disease, partial or complete response. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |